RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants

1. ACIP recommends Merck's Enflonsia for infants against RSV. 2. Merck’s shot shows over 84% reduction in RSV-related hospitalizations. 3. FDA approval boosts confidence in the efficacy of Enflonsia. 4. Controversy exists with critics questioning safety of Merck's vaccine. 5. Enflonsia will compete against Sanofi and AstraZeneca's Beyfortus.